Ascendis To Present First Results From Platinum-Resistant Ovarian Cancer Cohort Of The Phase 1/2 IL-Believe Trial At ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S (NASDAQ:ASND) announced promising initial data from its Phase 1/2 IL-Believe Trial for platinum-resistant ovarian cancer, showing a 29% clinical response rate with its TransCon IL-2 β/γ treatment. The treatment was generally well-tolerated, with most adverse events being mild.
September 13, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's initial data from the IL-Believe Trial shows a 29% response rate in heavily pre-treated ovarian cancer patients, indicating potential efficacy of TransCon IL-2 β/γ. The treatment was well-tolerated, which could positively impact ASND's stock.
The announcement of a 29% response rate in a challenging patient population suggests potential efficacy of Ascendis Pharma's treatment, which is a positive development. The well-tolerated nature of the treatment further supports its potential success, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100